logo
AI is Bringing New Hope to the Undiagnosed

AI is Bringing New Hope to the Undiagnosed

Fast Company2 days ago

If you or someone you love has faced a medical mystery—a child with unexplained symptoms, a diagnosis that never quite fits—you know the agony of waiting for answers. For many families, the search for a diagnosis can take years, filled with uncertainty, frustration, and fear. But today, something remarkable is happening behind the scenes: Artificial intelligence is quietly transforming how quickly and accurately we can find those answers.
The data dilemma
Over the past decade, the rise of genetic testing has given us unprecedented power to diagnose rare and complex diseases. However, sequencing a genome's worth of information generates a staggering amount of data. Imagine trying to find a single typo in a library of books. For doctors, making sense of this information can be labor intensive and time-consuming, and for families waiting for answers, every minute matters.
AI is helping us solve this data dilemma by reducing the manual burden on clinicians, increasing diagnostic yield, and making advanced genetic testing more accessible.
What this means for patients
In my time as a clinical geneticist, I've interpreted thousands of genome sequences. I can testify firsthand to how much efficiency we gain by leveraging AI in the process. At GeneDx, we're experimenting with AI tools that help us extract key clinical clues from patient records, prioritize which genetic variants are most likely to matter, and deliver faster, more precise answers for families searching for a diagnosis. This isn't some futuristic practice we expect to impact in the future – we're using this technology to help patients, today.
GeneDx CEO Katherine Stueland shared more information about how our laboratory is leveraging AI to improve patient care at the recent Fortune AI Summit. AI tools are working to put genetic diagnoses into the hands of families sooner by decreasing the amount of time it takes to interpret a genome sequence. We can support genetics providers so they can work more efficiently and serve more patients.
For families, the impact is profound. A faster diagnosis can mean earlier access to therapies, more informed medical management, and—perhaps most importantly—relief from the uncertainty that so often accompanies rare diseases. I've seen parents' shoulders drop in relief when they finally get an answer, and I've seen how that clarity can change the trajectory of a child's care. There is real hope in knowing that technology can bring comfort, direction, and a sense of community to families who have often felt alone in their search for answers.
The future is now
AI cannot replace the human touch offered by a team of experts, and thus, it's important to use a 'human-in-the-loop' approach, where every AI-generated insight is reviewed and validated by expert medical geneticists. This partnership between human insight and machine learning means medicine can move faster, delivering diagnoses in days instead of months—without sacrificing accuracy or patient care.
The key is to keep patients at the center of every innovation. Technology should empower, not overshadow, the human relationships that define great healthcare. With every advance, we're reminded that hope is not just a byproduct of progress—it's the reason we pursue it.
From diagnosis to discovery
The journey doesn't end with a diagnosis. AI is helping patients move faster toward new treatments, clinical trials, and discoveries. By partnering with biopharma and researchers, we're turning today's answers into tomorrow's cures.
As we celebrate the progress we've made, I encourage patients, doctors, and policymakers to look beyond the headlines. For patients and families, that might mean asking your doctor about genetic testing or sharing your story to help others on a similar journey. For clinicians, it's about staying curious and open to new tools that can enhance—not replace—your expertise and compassion. And for those shaping policy or developing technology, it's a call to champion innovation that is transparent, equitable, and always centered on the needs of real people.
AI in healthcare isn't a distant dream—it's a reality that's improving lives today. The future of medicine is here, and it's more hopeful, more human, and more connected than ever before.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

Yahoo

time41 minutes ago

  • Yahoo

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Scott Galloway has some choice metaphors to describe AI's impact on workers: 'I think of it as corporate Ozempic'
Scott Galloway has some choice metaphors to describe AI's impact on workers: 'I think of it as corporate Ozempic'

Yahoo

timean hour ago

  • Yahoo

Scott Galloway has some choice metaphors to describe AI's impact on workers: 'I think of it as corporate Ozempic'

NYU professor Scott Galloway thinks a lot about AI. Galloway shared some vivid metaphors to describe how AI is changing the workplace. He said to think of it like "corporate Ozempic" or the "East German Stasi with WiFi." AI is changing the workplace fast, making it harder than ever for employees and their bosses to keep up. Scott Galloway, a New York University Stern School of Business professor and host of the podcast The Prof G Pod, shared some of the metaphors he's come up with to describe AI's impact on the workplace in a discussion with Microsoft Chief Scientist Jaime Teevan and Greg Shove, the CEO of Section, an AI education company. Here are some of Galloway's best metaphors: The leadership and boards of many companies are using AI to cut costs. In this scenario, Galloway said he thinks of AI as having some of the same properties as GLP-1s. The "dark side" of AI lies in how easily it can identify low performers, Galloway said, comparing it to East Germany's Cold War-era secret police, notorious for their widespread surveillance. For the top 10% of the US labor force, however, Galloway thinks AI is a boon. Read the original article on Business Insider

NASA Satellite Glimpses Giant Volcano Peeking Above The Clouds of Mars
NASA Satellite Glimpses Giant Volcano Peeking Above The Clouds of Mars

Yahoo

timean hour ago

  • Yahoo

NASA Satellite Glimpses Giant Volcano Peeking Above The Clouds of Mars

A spacecraft's-eye view over the landscapes of Mars has just given us a first-of-its-kind glimpse of the giant, ancient edifice known as Arsia Mons. The NASA satellite Odyssey captured the enormous equatorial volcano as its tip peeked above the morning clouds of water ice – a common feature at this time of the Martian year, when the red planet is at its furthest point from the Sun on its slightly elliptical orbit. Arsia Mons belongs to a volcanic complex known as the Tharsis Montes; three shield volcanoes very close together in the Tharsis region of Mars. Arsia Mons is the tallest of the three, standing at a towering height of nearly 20 kilometers (12 miles). That's dramatically higher than any mountain on Earth, where the tallest peak above sea level (Mount Everest) stands 8.85 kilometers high and the tallest mountain, Mauna Kea, rises 9 kilometers above the sea floor. It also has around 30 times more volume than Earth's largest volcano, Mauna Loa – and it's not even the biggest volcano on Mars. Its activity is thought to have lasted billions of years, peaking around 150 million years ago. Odyssey usually has its cameras pointed down toward the surface of Mars. To obtain the new panorama, it had to rotate 90 degrees so that its camera pointed at the horizon. This angle is worth the effort: it allows scientists to make out layers and clouds in the thin Martian sky to better understand its atmospheric dynamics and processes. Clouds form around Arsia Mons when expanding air rises up the slopes of the mountain, rapidly cooling, allowing ice crystals to form. At Mars's current position in its journey around the Sun, a belt of clouds forms around the equator known as the aphelion cloud belt. Curiosity captured this phenomenon from the surface several years ago; the new Odyssey panorama gives us a spectacular view from above. "We picked Arsia Mons hoping we would see the summit poke above the early morning clouds," says aerospace engineer Jonathon Hill of Arizona State University. "And it didn't disappoint." The Universe's Missing Black Holes May Have Been Located Mysteriously Magnetic Moon Rocks Might Have an Explosive Origin Story Fiery Orange Gems From The Moon Reveal Secrets of Its Violent Past

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store